All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Prognomiq Inc. nearly doubled its fundraising to date with a new $46 million financing to further develop its multiomics platform to detect cancer and other complex diseases earlier in their development. The financing led by Bruker Corp. along with new investor Catalio Capital Management brought total funds raised $101 million since the company’s founding in 2020.
Freenome Holdings Inc. has landed $290 million from Basel, Switzerland-based Roche Holding AG to advance its multiomics platform for early cancer detection. The multimillion financing deal brings San Francisco-based Freenome’s total funding to more than $1.1 billion, securing its status as a unicorn company. It comes on the heels of a series D raise in December 2021, which netted Freenome $300 million from investors including Perceptive Advisors and RA Capital Management.
Rebus Biosystems Inc. introduced the first commercially available spatial omics platform at the Advances in Genome Biology and Technology virtual meeting on March 1. The Rebus Esper builds on the company’s Synthetic Aperture Optics (SAO) technology that enables rapid quantitative analysis of tens of millions of cellular features across hundreds of thousands of cells in their native tissue contexts.
Bluestar Genomics Inc. and the University of Chicago revealed the publication of a genome-wide 5-hydroxymethylcytosine (5hmC) map across multiple human tissue types. In the report, published Dec. 2, 2020, in Nature Communications, the researchers detailed the development of the map by characterizing the genomic distributions of 5hmC in 19 human tissues derived from 10 organ systems.
Rebus Biosystems Inc. has closed a $20 million series B fundraising round. The financing round was led by Illumina Ventures with participation by Lifecore Partners, Ncore Ventures, Xolon Invest, Ctk Investments, Ray Co. Ltd., Seegene Medical Foundation, Labgenomics Co. Ltd. and Timefolio Asset Management. Rebus builds spatial omics tools, assays and platforms. The company plans to use the new funding to support commercialization of its spatial omics solution and expansion of its marketing, sales, research, and product development teams, said Rebus CEO Paul Sargeant. Rebus plans to launch its automated, standalone Rebus Biosystems instrument and optimized assay kits for spatial transcriptomics early in 2021.
The Lifetime Initiative released a roadmap to revolutionize health care in Europe by implementing cell-based interceptive medicine in a perspective article published Sept. 7 in Nature.
Francis Collins, director of the U.S. NIH, said in a public forum that the agency is "really bullish" about precision medicine. However, while precision medicine requires mounds of data, which soon may be available, Collins said the NIH All of Us research program has drawn the interest of more than 300,000 willing participants to date, adding that the target enrollment of 1 million should be accomplished before the end of 2022.
RSS
